MA29542B1 - Traitement des maladies hepatiques dans la pathogenese desquelles le fer joue un role - Google Patents
Traitement des maladies hepatiques dans la pathogenese desquelles le fer joue un roleInfo
- Publication number
- MA29542B1 MA29542B1 MA30467A MA30467A MA29542B1 MA 29542 B1 MA29542 B1 MA 29542B1 MA 30467 A MA30467 A MA 30467A MA 30467 A MA30467 A MA 30467A MA 29542 B1 MA29542 B1 MA 29542B1
- Authority
- MA
- Morocco
- Prior art keywords
- treatment
- pathogenesis
- role
- hepatic diseases
- iron plays
- Prior art date
Links
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 title abstract 4
- 201000010099 disease Diseases 0.000 title abstract 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title abstract 4
- 230000002440 hepatic effect Effects 0.000 title abstract 2
- 229910052742 iron Inorganic materials 0.000 title abstract 2
- 230000008506 pathogenesis Effects 0.000 title abstract 2
- 230000001476 alcoholic effect Effects 0.000 abstract 2
- 208000006154 Chronic hepatitis C Diseases 0.000 abstract 1
- 208000005176 Hepatitis C Diseases 0.000 abstract 1
- 239000003443 antiviral agent Substances 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- BOFQWVMAQOTZIW-UHFFFAOYSA-N deferasirox Chemical compound C1=CC(C(=O)O)=CC=C1N1C(C=2C(=CC=CC=2)O)=NC(C=2C(=CC=CC=2)O)=N1 BOFQWVMAQOTZIW-UHFFFAOYSA-N 0.000 abstract 1
- 208000010710 hepatitis C virus infection Diseases 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 230000003612 virological effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4196—1,2,4-Triazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Virology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Addiction (AREA)
- Psychiatry (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Molecular Biology (AREA)
- Gastroenterology & Hepatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US68584805P | 2005-05-31 | 2005-05-31 | |
| US69280805P | 2005-06-22 | 2005-06-22 | |
| US74678606P | 2006-05-09 | 2006-05-09 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA29542B1 true MA29542B1 (fr) | 2008-06-02 |
Family
ID=37106984
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA30467A MA29542B1 (fr) | 2005-05-31 | 2007-12-10 | Traitement des maladies hepatiques dans la pathogenese desquelles le fer joue un role |
Country Status (16)
| Country | Link |
|---|---|
| US (3) | US20080199428A1 (it) |
| EP (1) | EP1893198A2 (it) |
| JP (2) | JP2008542380A (it) |
| KR (2) | KR20080003933A (it) |
| AU (1) | AU2006252718B2 (it) |
| BR (1) | BRPI0610873A2 (it) |
| CA (1) | CA2608709A1 (it) |
| CR (1) | CR9454A (it) |
| EA (1) | EA014772B1 (it) |
| IL (1) | IL187000A0 (it) |
| MA (1) | MA29542B1 (it) |
| MX (1) | MX2007015085A (it) |
| NO (1) | NO20076595L (it) |
| SM (1) | SMAP200700061A (it) |
| TN (1) | TNSN07447A1 (it) |
| WO (1) | WO2006130532A2 (it) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MY164523A (en) | 2000-05-23 | 2017-12-29 | Univ Degli Studi Cagliari | Methods and compositions for treating hepatitis c virus |
| EP1736478B1 (en) | 2000-05-26 | 2015-07-22 | IDENIX Pharmaceuticals, Inc. | Methods and compositions for treating flaviviruses and pestiviruses |
| CN1678326A (zh) | 2002-06-28 | 2005-10-05 | 埃迪尼克斯(开曼)有限公司 | 用于治疗黄病毒感染的2'－c－甲基－3'－o－l－缬氨酸酯核糖呋喃基胞苷 |
| NZ537662A (en) | 2002-06-28 | 2007-10-26 | Idenix Cayman Ltd | 2'-C-methyl-3'-O-L-valine ester ribofuranosyl cytidine for treatment of flaviviridae infections |
| LT1576138T (lt) | 2002-11-15 | 2017-06-26 | Idenix Pharmaceuticals Llc | 2`-šakoti nukleozidai derinyje su interferonu ir flaviviridae mutacija |
| AU2003300901A1 (en) | 2002-12-12 | 2004-06-30 | Idenix (Cayman) Limited | Process for the production of 2'-branched nucleosides |
| CN101242857A (zh) * | 2005-08-15 | 2008-08-13 | 弗·哈夫曼-拉罗切有限公司 | 用于HBV治疗的PEG-IFNa和利巴韦林 |
| WO2008065123A2 (en) * | 2006-11-29 | 2008-06-05 | Novartis Ag | Polymorphic forms of deferasirox ( icl670a) |
| EP1927591A1 (en) * | 2006-11-29 | 2008-06-04 | Novartis AG | Polymorphic Forms of Deferasirox (ICL670) |
| EP2680859B1 (en) * | 2011-03-02 | 2022-04-27 | Jerome Schentag | Compositions, methods of treatment and diagnostics for treatment of hepatic steatosis alone or in combination with a hepatitis c virus infection |
| EP2583677A3 (en) | 2011-10-21 | 2013-07-03 | Abbvie Inc. | Methods for treating HCV comprising at least two direct acting antiviral agent, ribavirin but not interferon. |
| US8466159B2 (en) | 2011-10-21 | 2013-06-18 | Abbvie Inc. | Methods for treating HCV |
| DE202012012955U1 (de) | 2011-10-21 | 2014-07-14 | Abbvie Inc. | Eine Kombination aus mindestens zwei direkt wirkenden antiviralen Wirkstoffen (DAAs) für die Verwendung zur Behandlung von HCV |
| US8492386B2 (en) | 2011-10-21 | 2013-07-23 | Abbvie Inc. | Methods for treating HCV |
| US20130108573A1 (en) * | 2011-10-28 | 2013-05-02 | Lumena Pharmaceuticals, Inc. | Bile Acid Recycling Inhibitors for Treatment of Hypercholemia and Cholestatic Liver Disease |
| EP3119401A4 (en) * | 2014-03-21 | 2017-12-13 | Tobira Therapeutics, Inc. | Cenicriviroc for the treatment of fibrosis |
| EA201892448A1 (ru) | 2016-04-28 | 2019-06-28 | Эмори Юниверсити | Алкинсодержащие нуклеотидные и нуклеозидные терапевтические композиции и связанные с ними способы применения |
| GB202005054D0 (en) | 2020-04-06 | 2020-05-20 | Nemysis Ltd | Carboxylate Ligand Modified Ferric Iron Hydroxide Compositions for Use in the Treatment or Prevention of Iron Deficiency Associated with Liver Diseases |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MY129541A (en) * | 1996-06-25 | 2007-04-30 | Novartis Ag | Substituded 3,5-diphenyl-1,2,4-triazoles and their use as pharmaceutical metal chelators |
| JP4125011B2 (ja) * | 2002-01-22 | 2008-07-23 | 株式会社 伊藤園 | 過剰鉄起因肝障害予防・治療剤及び過剰鉄起因肝障害予防・治療飲食物 |
-
2006
- 2006-05-30 JP JP2008514737A patent/JP2008542380A/ja not_active Withdrawn
- 2006-05-30 KR KR1020077027922A patent/KR20080003933A/ko not_active Withdrawn
- 2006-05-30 EA EA200702384A patent/EA014772B1/ru not_active IP Right Cessation
- 2006-05-30 SM SM200700061T patent/SMAP200700061A/it unknown
- 2006-05-30 WO PCT/US2006/020677 patent/WO2006130532A2/en not_active Ceased
- 2006-05-30 EP EP06771445A patent/EP1893198A2/en not_active Withdrawn
- 2006-05-30 AU AU2006252718A patent/AU2006252718B2/en not_active Ceased
- 2006-05-30 MX MX2007015085A patent/MX2007015085A/es not_active Application Discontinuation
- 2006-05-30 US US11/913,678 patent/US20080199428A1/en not_active Abandoned
- 2006-05-30 CA CA002608709A patent/CA2608709A1/en not_active Abandoned
- 2006-05-30 BR BRPI0610873-3A patent/BRPI0610873A2/pt not_active IP Right Cessation
- 2006-05-30 KR KR1020107000444A patent/KR101174966B1/ko not_active Expired - Fee Related
-
2007
- 2007-10-19 CR CR9454A patent/CR9454A/es unknown
- 2007-10-29 IL IL187000A patent/IL187000A0/en unknown
- 2007-11-29 TN TNP2007000447A patent/TNSN07447A1/en unknown
- 2007-12-10 MA MA30467A patent/MA29542B1/fr unknown
- 2007-12-20 NO NO20076595A patent/NO20076595L/no not_active Application Discontinuation
-
2009
- 2009-12-18 US US12/641,690 patent/US20100098662A1/en not_active Abandoned
-
2012
- 2012-12-20 US US13/721,196 patent/US20130109730A1/en not_active Abandoned
- 2012-12-20 JP JP2012277849A patent/JP5869469B2/ja not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| EA014772B1 (ru) | 2011-02-28 |
| WO2006130532A2 (en) | 2006-12-07 |
| JP2008542380A (ja) | 2008-11-27 |
| US20080199428A1 (en) | 2008-08-21 |
| KR20080003933A (ko) | 2008-01-08 |
| NO20076595L (no) | 2007-12-20 |
| TNSN07447A1 (en) | 2009-03-17 |
| JP2013082726A (ja) | 2013-05-09 |
| MX2007015085A (es) | 2008-01-17 |
| CR9454A (es) | 2008-04-16 |
| KR20100018057A (ko) | 2010-02-16 |
| KR101174966B1 (ko) | 2012-08-17 |
| EP1893198A2 (en) | 2008-03-05 |
| EA200702384A1 (ru) | 2008-06-30 |
| CA2608709A1 (en) | 2006-12-07 |
| AU2006252718B2 (en) | 2010-04-15 |
| WO2006130532A3 (en) | 2007-11-22 |
| SMAP200700061A (it) | 2007-12-28 |
| JP5869469B2 (ja) | 2016-02-24 |
| IL187000A0 (en) | 2008-02-09 |
| AU2006252718A1 (en) | 2006-12-07 |
| US20130109730A1 (en) | 2013-05-02 |
| US20100098662A1 (en) | 2010-04-22 |
| BRPI0610873A2 (pt) | 2010-08-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA29542B1 (fr) | Traitement des maladies hepatiques dans la pathogenese desquelles le fer joue un role | |
| EP1730163A4 (en) | Pharmaceutical salts of 3-O- (3,3-dimethylsuccinyl) betulinic acid | |
| MA28437B1 (fr) | Composes et leurs procedes d'utilisation | |
| DE60111539D1 (de) | Pharmazeutische zusammensetzung enthaltend ein 5-aminolaevulinsäure-ester als photochemotherapeutikum und ein mucoadhäsivum | |
| MA31496B1 (fr) | Inhibiteurs macrocycliques innovants de la replication du virus de l'hepatite c | |
| EA200702198A1 (ru) | Фармацевтические составы | |
| MA34013B1 (fr) | Inhibiteurs du virus de l'hépatite c | |
| ECSP066959A (es) | Compuestos macrociclicos como inhibidores de la replicación viral | |
| CY1111755T1 (el) | Μεθοδοι και συνθεσεις για μειωση ποσοτητων ιικου γονιδιωματος hcv σε ενα κυτταρο στοχο | |
| MA31497B1 (fr) | Nouveaux inhibiteurs peptidiques de la replication du virus de l'hepatite c | |
| EP1932514A4 (en) | PHARMACEUTICAL PREPARATION FOR TOPICAL APPLICATION TO SKIN WITH PHOSPHORYLATED SUGAR | |
| MA34765B1 (fr) | Antagonistes des récepteurs de l'acide lysophosphatidique et utilisations de ceux-ci | |
| BR0317572A (pt) | Benzoxazinas e seus derivados como inibidores de pi3ks | |
| DK2024367T3 (da) | Tetrahydropyrrolopyrimidindioner og deres anvendelse som inhibitorer af human neutrofil elastase | |
| BRPI0508579A (pt) | composto, composição farmacêutica, e, uso de um composto | |
| MA29600B1 (fr) | Utilisation de sanglifehrine dans le virus de l'hepatite c | |
| NO20076405L (no) | Anvendelse av 24-nor-UDCA | |
| DK1893187T3 (da) | Forbedrede antimikrobielle peroxidasepræparater | |
| DE502005010427D1 (de) | Physiologisch aktive zusammensetzung gegen diabetes | |
| MA31130B1 (fr) | Combinaison comprenant un chelatant du fer et un agent antineoplasique et ses applications | |
| EP1930002A4 (en) | USE OF HYDROXYBENZOIC ACID ESTERS AND ANALOGUES FOR THE PRODUCTION OF A MEDICAMENT FOR THE PREVENTION AND TREATMENT OF VIRUS INFECTIONS | |
| MA33563B1 (fr) | 5-(3,4-dichloro-phényl)-n-(2-hydroxy-cyclohexyl)-6-(2,2,2-trifluoro-éthoxy)-nicotinamide et ses sels utilisés comme agents augmentant le cholestérol hdl | |
| NO20080890L (no) | Sammensetninger for a redusere forekomsten av medikamentindusert arytmi | |
| BRPI0608287A2 (pt) | agente endoparasiticida | |
| WO2007044700A3 (en) | Protectant combinations for reducing toxicities |